Yahoo
NasdaqCM - Delayed Quote USD

Psyence Biomedical Ltd. (PBM)

6.25 -0.34 (-5.16%)
At close: May 1 at 4:00:03 PM EDT
6.03 -0.22 (-3.52%)
After hours: May 1 at 7:59:46 PM EDT
Chart Range Bar
Loading chart for PBM
  • Previous Close 6.59
  • Open 6.59
  • Bid 4.62 x 100
  • Ask 7.55 x 100
  • Day's Range 5.80 - 6.94
  • 52 Week Range 1.92 - 468.36
  • Volume 1,062,081
  • Avg. Volume 2,690,618
  • Market Cap (intraday) 14.333M
  • Beta (5Y Monthly) 0.31
  • PE Ratio (TTM) --
  • EPS (TTM) -389.98
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

www.psyencebiomed.com

12

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview: PBM

Trailing total returns as of 5/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PBM
78.75%
S&P 500 (^GSPC)
5.62%

1-Year Return

PBM
95.45%
S&P 500 (^GSPC)
29.01%

3-Year Return

PBM
100.00%
S&P 500 (^GSPC)
73.47%

5-Year Return

PBM
100.00%
S&P 500 (^GSPC)
72.92%

Statistics: PBM

View More

Valuation Measures

Annual
As of 11/26/2025
  • Market Cap

    14.33M

  • Enterprise Value

    14.90M

  • Trailing P/E

    0.04

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    1.21

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    6.32

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -34.44%

  • Return on Equity (ttm)

    -74.29%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -3.94M

  • Diluted EPS (ttm)

    -389.98

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.15M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -4.01M

Compare To: PBM

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: PBM

Fair Value

6.25 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: